A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson's disease when administered once daily for 28 weeks.

Trial Profile

A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson's disease when administered once daily for 28 weeks.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Sarsasapogenin (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms CONFIDENT-PD
  • Sponsors Phytopharm
  • Most Recent Events

    • 17 Jul 2013 According to a Phytopharm media release, sarsasapogenin did not demonstrate clinical efficacy in this trial. Full results will be published in due course.
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Apr 2012 Phytopharm is on track to complete this study during December 2012. Results are expected in February 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top